TY - JOUR
T1 - Global DNA methylation and the association between metal exposure and chronic kidney disease
AU - Hsueh, Yu Mei
AU - Chen, Wei Jen
AU - Lee, Hui Ling
AU - Huang, Ya Li
AU - Shiue, Horng Sheng
AU - Hsu, Sheng Lun
AU - Chen, Hsi Hsien
AU - Lin, Ying Chin
N1 - Funding Information:
This study was supported by grants from the Ministry of Science and Technology of Taiwan (MOST 106-2314-B-038-066, MOST 107-2320-B-039-010, MOST 106-2314-B-002-235-MY3, MOST 107-2314-B-038-073, MOST 108-2314-B-038 -089, MOST 109-2314-B-038-081, MOST 109-2314-B-038-067, and MOST 110-2314-B-038-054). This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Publisher Copyright:
Copyright © 2023 Hsueh, Chen, Lee, Huang, Shiue, Hsu, Chen and Lin.
PY - 2023
Y1 - 2023
N2 - Introduction: Prior studies indicate that exposure to metals may alter DNA methylation. Evidence also shows that global DNA methylation is associated with chronic kidney disease (CKD). This study aimed to examine the association between CKD and 5-methyl-2-deoxycytidine (5mdC, %), a marker of global DNA methylation, and to evaluate the interaction between metal exposures and 5mdC (%) on CKD. We also explored the mediation effect of 5mdC (%) on the association between metal exposures and renal function (i.e., estimated glomerular filtration rate, eGFR). Methods: A total of 218 CKD patients and 422 controls were recruited in this case–control study. 5mdC (%), concentrations of blood lead and cadmium, plasma selenium, and total urinary arsenic were measured. CKD cases were clinically defined among patients with eGFR <60 mL/min/1.73 m2 for at least 3 months and without hemodialysis. Odds ratio (OR) and 95% confidence interval (CI) were estimated by logistic regression models to examine the association between metal exposures, 5mdC (%), and CKD, adjusted for confounders. Multivariable linear regression models were used to examine associations between metal exposures, 5mdC (%), and eGFR. Results and Discussion: CKD cases compared to controls had 6.06-fold (95% CI: 3.11–11.81) higher odds of having high blood cadmium and high 5mdC (%) levels. A positive interaction on an additive scale was identified between blood cadmium and 5mdC (%) on CKD. Cases compared to controls had 4.73-fold (95% CI: 2.65–8.45) higher odds of having low plasma selenium and high 5mdC (%) levels; and a significant multiplicative interaction between plasma selenium and 5mdC (%) on CKD was observed. In addition, we found that blood lead and cadmium concentrations were positively associated, while plasma selenium concentrations were inversely associated, with 5mdC (%). The associations of blood lead and plasma selenium with eGFR were partially mediated by 5mdC (%). Our results suggest that 5mdC (%) may interact with plasma selenium and blood cadmium to influence the risk of CKD. The 5mdC (%) also potentially mediates the associations between exposure to metals and renal function.
AB - Introduction: Prior studies indicate that exposure to metals may alter DNA methylation. Evidence also shows that global DNA methylation is associated with chronic kidney disease (CKD). This study aimed to examine the association between CKD and 5-methyl-2-deoxycytidine (5mdC, %), a marker of global DNA methylation, and to evaluate the interaction between metal exposures and 5mdC (%) on CKD. We also explored the mediation effect of 5mdC (%) on the association between metal exposures and renal function (i.e., estimated glomerular filtration rate, eGFR). Methods: A total of 218 CKD patients and 422 controls were recruited in this case–control study. 5mdC (%), concentrations of blood lead and cadmium, plasma selenium, and total urinary arsenic were measured. CKD cases were clinically defined among patients with eGFR <60 mL/min/1.73 m2 for at least 3 months and without hemodialysis. Odds ratio (OR) and 95% confidence interval (CI) were estimated by logistic regression models to examine the association between metal exposures, 5mdC (%), and CKD, adjusted for confounders. Multivariable linear regression models were used to examine associations between metal exposures, 5mdC (%), and eGFR. Results and Discussion: CKD cases compared to controls had 6.06-fold (95% CI: 3.11–11.81) higher odds of having high blood cadmium and high 5mdC (%) levels. A positive interaction on an additive scale was identified between blood cadmium and 5mdC (%) on CKD. Cases compared to controls had 4.73-fold (95% CI: 2.65–8.45) higher odds of having low plasma selenium and high 5mdC (%) levels; and a significant multiplicative interaction between plasma selenium and 5mdC (%) on CKD was observed. In addition, we found that blood lead and cadmium concentrations were positively associated, while plasma selenium concentrations were inversely associated, with 5mdC (%). The associations of blood lead and plasma selenium with eGFR were partially mediated by 5mdC (%). Our results suggest that 5mdC (%) may interact with plasma selenium and blood cadmium to influence the risk of CKD. The 5mdC (%) also potentially mediates the associations between exposure to metals and renal function.
KW - 5-methyl-2-deoxycytidine
KW - arsenic
KW - cadmium
KW - chronic kidney disease
KW - lead
KW - selenium
UR - http://www.scopus.com/inward/record.url?scp=85161429957&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85161429957&partnerID=8YFLogxK
U2 - 10.3389/fpubh.2023.1104692
DO - 10.3389/fpubh.2023.1104692
M3 - Article
C2 - 37304094
AN - SCOPUS:85161429957
SN - 2296-2565
VL - 11
JO - Frontiers in Public Health
JF - Frontiers in Public Health
M1 - 1104692
ER -